# Precipio Diagnostics (PRPO) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/PRPO
## Company Profile
- Ticker: PRPO
- Exchange: NASDAQ
- Sector: MedTech
- Location: United States
- Tags: MedTech, Oncology, Hematology
## Stock Data
- Close: 22.35 USD
- Market cap: 40180122.56 USD
- Last updated: 2026-08-11
## Business Overview
### Cancer Diagnostics Company
Precipio develops cancer diagnostic products and laboratory services. Its mission is to reduce diagnostic errors through more accurate testing products, optimized laboratory workflows, and clinical pathology services.
### Laboratory Services and Product Development
The company designs, tests, validates, and uses diagnostic technologies in its own laboratory before commercializing them as proprietary products for laboratories worldwide. Revenue is generated from both pathology services and diagnostic product sales.
### Integrated Business Model
Precipio combines services and products: the laboratory business provides a real-world clinical development environment, while the product business expands the reach of validated technologies. The release did not identify a specific future asset-level clinical or regulatory milestone.
## Why The Stock Is Moving

As of Aug 11, 2026, PRPO closed down 1.11% at $22.35. No new same-company headline was identified in the current news window.

## Future Catalysts

- Precipio’s catalysts are diagnostic product adoption and any update that clarifies whether the company can keep building a niche lab-testing business. The market will care about recurring test usage more than a single headline.

## Recent News
- 2026-07-31 20:00 EST — [Precipio Announces Q2-2026 Shareholder Update Call](https://biopharmsignal.com/news/PRPO/precipio-announces-q2-2026-shareholder-update-call-e822ad89) — Source: Precipio Diagnostics
- 2026-06-12 17:00 EST — [Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting](https://biopharmsignal.com/news/PRPO/precipio-is-requesting-shareholders-brokers-vote-today-to-avoid-costly-adjournme-a1496f3a) — Source: Precipio Diagnostics
- 2026-06-11 21:00 EST — [Precipio to Present at the Planet MicroCap Las Vegas](https://biopharmsignal.com/news/PRPO/precipio-to-present-at-the-planet-microcap-las-vegas-03ee4335) — Source: Precipio Diagnostics
- 2026-05-14 21:00 EST — [Precipio Announces Q1 2026 Financial Results](https://biopharmsignal.com/news/PRPO/precipio-announces-q1-2026-financial-results-8999c84d) — Source: Precipio Diagnostics
- 2026-05-13 21:00 EST — [Management team’s 2025 market-based Options have vested](https://biopharmsignal.com/news/PRPO/management-team-s-2025-market-based-options-have-vested-466b0d25) — Source: Precipio Diagnostics